Pharmacology, Toxicology and Pharmaceutical Science
Amentoflavone
21%
Angiotensin Receptor Antagonist
45%
Anti-Inflammatory Drug
25%
Antiapoptotic
21%
Antiinfective Agent
25%
Antioxidant
25%
Bleeding
22%
Cardiovascular Disease
27%
Cefamandole
21%
Cefixime
21%
Cohort Study
80%
Community Pharmacy
21%
Coronavirinae
80%
Cross Sectional Study
32%
Cross-Sectional Study
81%
Cyclophosphamide
27%
Daptomycin
28%
Dipeptidyl Carboxypeptidase Inhibitor
45%
Disease Exacerbation
21%
Diseases
100%
Etanercept
21%
Favipiravir
65%
Hemoglobin A1c
25%
Heparin
21%
Hydroxychloroquine
21%
Infection
53%
Infection Rate
21%
Inflammatory Arthritis
21%
Insulin Dependent Diabetes Mellitus
21%
Ipilimumab
21%
Metastatic Melanoma
21%
Observational Study
21%
Pandemic
43%
Pharmaceutical Care
21%
Pharmacotherapy
26%
Pharmacy Practice
21%
Polypharmacy
21%
Prospective Cohort Study
21%
Retrospective Study
42%
Rheumatoid Arthritis
21%
SARS Coronavirus
34%
Shikonin
21%
Staphylococcus Hominis
24%
Talimogene Laherparepvec
21%
Tobramycin
21%
Toll Like Receptor 4
34%
Topical Corticosteroid
21%
Transcription Factor Nrf2
34%
Tumor Necrosis Factor Inhibitor
21%
Ustekinumab
43%
Nursing and Health Professions
Acute Coronary Syndrome
21%
Ambulatory Care
10%
Ampicillin
10%
Angiotensin Receptor
21%
Antiinfective Agent
21%
Artificial Respiration
10%
Cardiovascular Disease
21%
Clinical Outcome
15%
Cohort Analysis
46%
Confidence Interval
29%
Cost Effectiveness Analysis
21%
Cross-Sectional Study
78%
Daptomycin
10%
Diabetes Mellitus
24%
Dipeptidyl Carboxypeptidase Inhibitor
22%
Diseases
32%
Enkephalinase Inhibitor
21%
Gram Negative Sepsis
21%
Gram Staining
10%
Hazard Ratio
34%
Health Care
10%
Health Care Personnel
15%
Health Care Quality
12%
Heart Failure with Reduced Ejection Fraction
21%
Hospital Readmission
21%
Infection
24%
Inflammatory Arthritis
21%
Length of Stay
21%
Medication Compliance
16%
Medication Error
20%
Meta Analysis
21%
Nutrition Policy
10%
Odds Ratio
37%
Oxygen Therapy
10%
Pandemic
13%
Patient Compliance
21%
Patient Health Questionnaire 9
10%
Patient Referral
21%
Patient with Diabetes
23%
Patient with Type 2 Diabetes
23%
Pharmacy Student
21%
Pralidoxime Mesilate
21%
Primary Health Care
24%
Propensity Score
45%
Quality of Life
21%
Rheumatoid Arthritis
21%
Sample Size
10%
Self Care
32%
Survival Analysis
24%
Telemedicine
54%
Medicine and Dentistry
Analysis of Covariance
8%
Angiotensin Receptor
21%
Antibiotics
13%
Antiinfective Agent
21%
Arm
22%
Artificial Respiration
10%
Blood Culture
9%
Cardiovascular Disease
19%
Cardiovascular System
21%
COVID-19
86%
Crohn's Disease
21%
Cross Sectional Study
24%
Diabetes
57%
Disease Exacerbation
10%
Diseases
14%
Drug Megadose
10%
Enkephalinase Inhibitor
21%
Extubation
8%
Ferritin
9%
Glycemic Control
21%
Gram Negative Sepsis
21%
Gram Staining
15%
Hazard Ratio
27%
Heart Failure with Reduced Ejection Fraction
10%
Hemoglobin A1c
21%
Human immunodeficiency virus
21%
Infection
46%
Inflammatory Arthritis
21%
Intensive Care Unit
13%
Iron
21%
Iron Supplement
12%
Maturity Onset Diabetes of the Young
33%
Medication Error
15%
Odds Ratio
13%
Osteomyelitis
21%
Patient Health Questionnaire 9
12%
Patient with Type 2 Diabetes
21%
Pediatrics
21%
Pediatrics Patient
11%
Propensity Score Matching
37%
Retrospective Cohort Study
21%
Retrospective Study
27%
Rheumatoid Arthritis
21%
Severe Acute Respiratory Syndrome Coronavirus 2
11%
Sickle-Cell Disease
21%
Supportive Care
21%
Thromboprophylaxis
21%
Tocilizumab
21%
Total Iron-Binding Capacity
9%
Tumor Necrosis Factor
9%
